NUVBNuvation Bio Inc.

$5.00+55% 1Y

$5.00

$3.0152 weeks$9.54

NUVB in its own filings

NUVB's filing record carries 2 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.

115

Events found in the filings · across 398 filings · the record starts in 2020

Hard flags: 2
Hard flags
Most recent filing: Aug 6, 2026
Most recent filing · Form 8-K
Record starts: Jul 6, 2020
Record starts · the earliest filing Ryufin holds for this name

Details›

Next results filingsame week as a year ago: expected around Nov 2, 2026
Restatement admitted (non-reliance)historical: 2021-05-14
Change in certifying accountanthistorical: 2021-02-12
Security removed from listing or deregistered2 occurrences · usually a matured note or preferred class, not the common shares: 2026-02-10
SEC comment-letter activity14 occurrences: 2024-08-12

SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.

What the company said

The company's own words from its current reports to the SEC, newest first

Aug 6, 2026Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
Jul 6, 2026On July 6, 2026, the Company issued a press release announcing the issuance of the additional Notes pursuant to the Greenshoe Exercise and the entry into the additional capped call confirmations.New debt or off-balance-sheet obligation · Form 8-K
Jun 30, 2026Completion of Convertible Senior Notes Offering On June 30, 2026, Nuvation Bio Inc. (the “Company”) completed its registered underwritten public offering (the “Offering”) of $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due 2032 (the “Notes”), pursuant to the Underwriting Agreement, dated …Material agreement entered · Form 8-K
May 4, 2026Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
Mar 2, 2026Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update.Earnings release · press release
Jan 12, 2026On January 11, 2026, Nuvation Bio Inc. (the “Company”) entered into a License and Collaboration Agreement (the “License Agreement”) with Eisai Co., Ltd. (“Eisai”)Material agreement entered · Form 8-K
Nov 26, 2025On November 26, 2025, the Company announced its decision to discontinue development of NUV-1511, the first compound in its first-of-its-kind drug-drug conjugate (DDC) program.Regulation FD disclosure · Form 8-K
Nov 17, 2025On November 8, 2025, positive results from a Phase 2 study of safusidenib in Japanese patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant gliomas were published in the online journal of Neuro-Oncology.Regulation FD disclosure · Form 8-K
Nov 3, 2025Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update.Earnings release · press release